Challenges in clinical trials for high-risk but curable prostate cancer

Cancer. 2024 May 1;130(9):1575-1576. doi: 10.1002/cncr.35245. Epub 2024 Feb 10.

Authors

Tanya Barauskas Dorff¹, Alan H Bryce²

Affiliations

¹ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
² Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.

PMID: 38340332
DOI: 10.1002/cncr.35245

No abstract available

Keywords: androgen‐deprivation therapy; clinical trial recruitment and retention; patient advocate; prostate cancer; prostatectomy.

Publication types

Editorial

MeSH terms

Androgen Antagonists / therapeutic use
Clinical Trials as Topic
Humans
Male
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / therapy

Substances

Androgen Antagonists
Prostate-Specific Antigen